In the shadowy underbelly of biotech, where giants like Pfizer and Moderna hog the spotlight with their billion-dollar vaccines, a pint-sized rebel is brewing a storm that could redefine gastrointestinal care. Evoke Pharma (NASDAQ: EVOK), trading at a tantalizing $5.96 as of August 18, 2025, isn’t just a stock—it’s a ticking time bomb of innovation, poised to detonate in the face of a $10 billion diabetic gastroparesis market. Forget the cookie-cutter pharma plays; EVOK’s Gimoti nasal spray is the guerrilla warrior bypassing broken digestive systems, delivering relief where pills fail. With Q2 2025 sales skyrocketing 47% to $3.752 million and analysts eyeing an $18 target (a 200%+ upside), this micro-cap dynamo is the ultimate contrarian bet. Buckle up: EVOK isn’t riding the wave—it’s the